CRISPR Therapeutics AG (CRSP) Retained Earnings (2015 - 2026)

CRISPR Therapeutics AG has disclosed Retained Earnings across 12 years of filings, most recently posting -$2.2 billion for Q2 2026.

• In Q2 2026, Retained Earnings fell 26.37% year-over-year to -$2.2 billion; the TTM figure through Jun 2026 stood at -$2.2 billion (down 26.37% YoY), while the FY2025 annual figure was -$1.9 billion, down 42.58% from the prior year.
• Retained Earnings came in at -$2.2 billion for Q2 2026 at CRISPR Therapeutics AG, down from -$2.1 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$375.1 million in Q1 2022 to a low of -$2.2 billion in Q2 2026.
• Average Retained Earnings over 5 years is -$1.3 billion, with a median of -$1.2 billion recorded in 2024.
• The largest YoY upside for Retained Earnings was 45.37% in 2022 against a maximum downside of 1245.45% in 2022.
• Over 5 years, Retained Earnings stood at -$846.1 million in 2022, then slipped by 18.16% to -$999.7 million in 2023, then sank by 36.64% to -$1.4 billion in 2024, then slumped by 42.58% to -$1.9 billion in 2025, then retreated by 10.99% to -$2.2 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$2.2 billion in Q2 2026, -$2.1 billion in Q1 2026, and -$1.9 billion in Q4 2025.